Brief: EyePoint, Rallybio On Research Collaboration To Evaluate C5, Durasert Tech
27/02/2023 12:08
Feb 27 (Reuters) - EyePoint Pharmaceuticals Inc
EYPT.O :
* EYEPOINT AND RALLYBIO ANNOUNCE RESEARCH COLLABORATION TO
EVALUATE RALLYBIO’S INHIBITOR OF COMPLEMENT COMPONENT 5 (C5) AND
EYEPOINT’S PROPRIETARY DURASERT® TECHNOLOGY FOR SUSTAINED
INTRAOCULAR DELIVERY IN GEOGRAPHIC ATROPHY
Source text for Eikon: ID:nBw6vlwvca
Further company coverage: EYPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rallybio
See all newsNASDAQ RESUMED AT 08:48 AM
Brief: Rallybio Corporation And Avenzo Therapeutics Announce Merger Agreement To Advance Next-Generation Oncology Therapies And $215 Million Concurrent Private Placement
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE-Mirum Pharma
U.S. STOCKS ON THE MOVE-Mirum Pharma, eBay, FedEx